Skip to content
The Policy VaultThe Policy Vault

SutentMedica

Medullary thyroid carcinoma

Initial criteria

  • age ≥ 18 years
  • Patient has tried at least one systemic therapy (e.g., vandetanib, cabozantinib, selpercatinib, pralsetinib)

Approval duration

1 year